THERAPY DOSSIER · th-ece00a166da8

Cypin activators H9 and G5 (N-benzoyl piperazines); cypin inhibitor B9 as comparator

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30031156 ↗2018Reported benefit

Cypin: A novel target for traumatic brain injury.

MouseTBIControlled cortical impactC57BL/6MaleDirect intrahippocampal injection, ipsilateral hippocampus (X -1.9, Y 1.4, Z -1.6)200 micromolar in artificial cerebrospinal fluid vehicle, 1…One hour after cortical impact

Model: Controlled cortical impact over the left parietotemporal cortex with dura intact; mild (1.0 mm depth, 0.4-0.5 m/s) and moderate (1.0 mm depth, 2.4-5.0 m/s) severities, behavioural work used moderate impact

Both cypin activators significantly improved freezing behaviour five days after injury relative to vehicle injured and untreated injured mice (H9 versus vehicle injured p<0.0001; G5 versus vehicle injured p=0.0022), whereas the inhibitor B9 gave no improvement (p>0.9).

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…